Send to

Choose Destination
Malawi Med J. 2016 Sep;28(3):139-149.

Four artemisinin-based treatments in African pregnant women with malaria.

Author information

Center for Global Health Research, Kumasi, Ghana.
Clinical Trial Unit Nanoro, Nanoro, Burkina Faso.
College of Medicine, University of Malawi, Blantyre, Malawi.
Department of Pharmaceutical and Pharmacologic Sciences, KU Leuven, Leuven, Belgium; Institute of Tropical Medicine, Antwerp, Belgium.
Hubert Kairuki Memorial University, Dar es Salaam, Tanzania.
Juaben Government Hospital, Juaben, Ghana.
Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Institute of Tropical Medicine, Antwerp, Belgium.
Institute of Tropical Medicine, Antwerp, Belgium; Menzies School of Health Research, Darwin, NT, Australia.
International Health Unit, University of Antwerp, Antwerp, Belgium.
Institute of Tropical Medicine, Antwerp, Belgium; Medical Research Council Unit, Fajara, Gambia; London School of Hygiene and Tropical Medicine, London, United Kingdom.
Tropical Diseases Research Center, Ndola, Zambia.



Information regarding the safety and efficacy of artemisinin combination treatments for malaria in pregnant women is limited, particularly among women who live in sub-Saharan Africa.


We conducted a multicenter, randomized, open-label trial of treatments for malaria in pregnant women in four African countries. A total of 3428 pregnant women in the second or third trimester who had falciparum malaria (at any parasite density and regardless of symptoms) were treated with artemether-lumefantrine, amodiaquine-artesunate, mefloquine-artesunate, or dihydroartemisinin-piperaquine. The primary end points were the polymerase-chain-reaction (PCR)-adjusted cure rates (i.e., cure of the original infection; new infections during follow-up were not considered to be treatment failures) at day 63 and safety outcomes.


The PCR-adjusted cure rates in the per-protocol analysis were 94.8% in the artemether-lumefantrine group, 98.5% in the amodiaquine-artesunate group, 99.2% in the dihydroartemisinin-piperaquine group, and 96.8% in the mefloquine-artesunate group; the PCR-adjusted cure rates in the intention-to-treat analysis were 94.2%, 96.9%, 98.0%, and 95.5%, respectively. There was no significant difference among the amodiaquine-artesunate group, dihydroartemisinin-piperaquine group, and the mefloquine-artesunate group. The cure rate in the artemether-lumefantrine group was significantly lower than that in the other three groups, although the absolute difference was within the 5-percentage-point margin for equivalence. The unadjusted cure rates, used as a measure of the post-treatment prophylactic effect, were significantly lower in the artemether-lumefantrine group (52.5%) than in groups that received amodiaquine-artesunate (82.3%), dihydroartemisinin-piperaquine (86.9%), or mefloquine-artesunate (73.8%). No significant difference in the rate of serious adverse events and in birth outcomes was found among the treatment groups. Drug-related adverse events such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred significantly more frequently in the mefloquine-artesunate group (50.6%) and the amodiaquine-artesunate group (48.5%) than in the dihydroartemisinin-piperaquine group (20.6%) and the artemether-lumefantrine group (11.5%) (P<0.001 for comparison among the four groups).


Artemether-lumefantrine was associated with the fewest adverse effects and with acceptable cure rates but provided the shortest posttreatment prophylaxis, whereas dihydroartemisinin-piperaquine had the best efficacy and an acceptable safety profile. (Funded by the European and Developing Countries Clinical Trials Partnership and others; number, NCT00852423.).


Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center